On April 4, 2022 Herantis Pharma Plc ("Herantis" or the "Company"), an innovative biotech company developing new disease modifying therapies for Parkinson’s disease, reported on 30 March 2022 the result of the offering of new shares (the "Placing Shares") in a directed share issue to institutional and other qualified investors (the "Directed Issue") (Press release, Herantis Pharma, APR 4, 2022, View Source;975-000-new-shares-registered-with-the-trade-register,c3539149 [SID1234611398]). In the Directed Issue, the Company issued a total of 975,000 Placing Shares. The Placing Shares have today been registered with the trade register maintained by the Finnish Patent and Registration Office.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the registration of the Placing Shares, the total number of registered shares in the Company is 12,078,568. The Placing Shares will be issued in the book-entry system (ISIN code FI4000087861) on or about 5 April 2022. After this, and registration on the investors’ book-entry accounts, the Placing Shares will confer shareholder rights in the Company. The Placing Shares are expected to be ready for delivery to the investors through Euroclear Finland Oy or, as applicable, through Euroclear Sweden AB on or about 5 April 2022.

Trading in the Placing Shares is expected to commence on Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden on or about 6 April 2022.